Cancer patients in the U.S. paid nearly $4 billion in out-of-pocket costs in 2014 and the disease cost the country $87.8 billion in cancer-related health care spending, a report by the American Cancer Society Cancer Action Network found.
Scientific organizations should establish an advisory board that would have the overarching mandate to foster research integrity across disciplines.
Eleven cancer research ideas have received funding from Pelotonia, the annual cycling event that has raised more than $130 million for cancer research at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
This week, the USPSTF issued its draft guidelines for prostate cancer screening. They propose shifting from task force's recommendation against routine prostate cancer screening to a recommendation for informed and shared decision-making in which the physician and patient discuss the real risks of harm and the potential for life saving benefit before deciding on screening.
MD Anderson Cancer Center's complaint against Pelotonia, filed Oct. 5, 2016, argues that the Ohio cancer fundraiser's use of the slogan “One Goal: End Cancer” infringes on the Houston hospital's “One goal. Stop cancer.” registered trademark.
Every August, cyclists sign up for the Pelotonia ride that meanders through Ohio's rolling hills.
FDA granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy.
FDA approved Zejula (niraparib), a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Gamida Cell announced that orphan drug designation has been granted by the European Medicines Agency's Committee for Orphan Medicinal Products regarding NiCord as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation.
Cota Healthcare announced the signing of a multi-year collaboration with Novartis Pharmaceuticals Corp. to help improve clinical and cost outcomes for breast cancer patients.
